Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
27 September 2022 - 9:00PM
Business Wire
Company to Host Virtual Investor Day with
Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m.
Eastern Time
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that data from the ongoing Phase 2 trial evaluating the
safety and efficacy of suprachoroidal (SC) administration using its
first VDC product candidate, belzupacap sarotalocan (AU-011), for
the first-line treatment of patients with early-stage choroidal
melanoma [indeterminate lesions and small choroidal melanoma
(IL/CM)] will be presented at the upcoming American Academy of
Ophthalmology (AAO) 2022 Annual Meeting being held September
30-October 3, 2022, in Chicago. The Company will also host a
virtual Investor Day on Monday, October 3, 2022, from 11:30 a.m. to
1:00 p.m. Eastern Time. Aura Biosciences’ executive management team
will be joined by three distinguished ocular oncology thought
leaders:
- Carol Shields, MD, Chief of the Ocular Oncology Service at
Wills Eye Hospital and Professor of Ophthalmology at Thomas
Jefferson University (USA)
- Ivana Kim, MD, MBA, Director of the Ocular Melanoma Center,
Massachusetts Eye and Ear & Associate Professor of
Ophthalmology, Harvard Medical School (USA)
- Martine Jager, MD, PhD, Professor of Ophthalmology, Leiden
University, (Netherlands) & Past President of the International
Society of Ocular Oncology and the Association for Research in
Vision and Ophthalmology
The program will include:
- Safety and efficacy results from the ongoing Phase 2 trial
evaluating suprachoroidal administration of belzupacap sarotalocan
for the potential first-line treatment of patients with early-stage
IL/CM
- Two-year visual acuity data from the retrospective matched case
control study of belzupacap sarotalocan vs. plaque
radiotherapy
- Preclinical data from a research collaboration with the
University of Leiden (Netherlands) highlighting the possibility of
using belzupacap sarotalocan in combination with immune checkpoint
inhibitors to treat primary and distant lesions by an abscopal
effect
Details for the Presentation at AAO:
Title: A Phase 2 Trial of AU-011, a First-in-Class
Targeted Therapy for Choroidal Melanoma via Suprachoroidal
Administration
Presenter: Ivana K. Kim, MD, Massachusetts Eye and
Ear
Session #: PA028
Location #: S405
Date/Time: Sunday, October 2, 2022, at 9:45 a.m. CST
The paper will be available here following the presentation.
Details for the Virtual Investor Day:
To access the virtual Investor Day, please dial (888) 660-6585
(U.S. and Canada) or (929) 203-0858 (international) at least 10
minutes prior to the start time and refer to conference ID 9748492.
A live video webcast will be available in the Investor section of
the Company’s website at
https://ir.aurabiosciences.com/events-and-presentations. A webcast
replay will also be available on the corporate website at the
conclusion of the call.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, belzupacap sarotalocan (AU-011),
consists of a virus-like particle conjugated with an anti-cancer
agent. Belzupacap sarotalocan is designed to selectively target and
destroy cancer cells and activates the immune system with the
potential to create long-lasting anti-tumor immunity. Belzupacap
sarotalocan is currently in development for ocular cancers, and
Aura plans to pursue development of belzupacap sarotalocan across
its ocular oncology franchise including for the treatment of
patients with choroidal metastasis. In addition, leveraging Aura’s
technology platform, Aura is developing belzupacap sarotalocan more
broadly across multiple cancers, including in patients with
non-muscle invasive bladder cancer (NMIBC). Aura is headquartered
in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220927005381/en/
Investor and Media:
Alex Dasalla Head of Investor Relations and Corporate
Communications adasalla@aurabiosciences.com
Argot Partners Matthew DeYoung aura@argotpartners.coma
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2024 to May 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From May 2023 to May 2024